Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02029209

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Updated 6 times since 2017 Last updated: Dec 14, 2016 Started: Dec 31, 2013 Primary completion: Mar 31, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Non-small Cell Lung Cancer and is currently ongoing. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China